Use of the gastrointestinal lipase inhibitor tetrahydrolipstatin, or orlistat,forthe manufacture of oral medicaments for treating or preventing type IIdiabetesmellitus, and the medicaments thus manufactured. The tetrahydrolipstatin isemployed in unit dosage form, formulated in an oral composition, and in therange offrom 60 to 720 mg of tetrahydrolipstatin per day.
